EVUSHELD: Protection for the Immunocompromised

EVUSHELD (tixagevimab & cilgavimab) is designed to offer protection from COVID-19 infections in patients who cannot mount an adequate immune response from COVID-19 vaccination (or for patients who cannot receive the vaccine for medical reasons).

EVUSHELD is specifically designed for patients that are immunocompromised.  Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

•  Active treatment for solid tumor and hematologic malignancies
• Receipt of solid-organ transplant and taking immunosuppressive therapy
• Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
• Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
• Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites,  transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)

Want an EVUSHELD injection?  Fill out the form below:

Who is eligible for EVUSHELD?

Patients who receive EVUSHELD must be at least 12 years of age and weigh 40 kg or more.

Patients that are undergoing cancer treatment or are taking medications for treatment of Multiple Sclerosis (MS), Rheumatoid Arthritis, Crohn’s Disease, and to prevent organ transplant rejection all qualify.

Medications for MS include:

• Ocrevus (ocrelizumab)
• Kesimpta (ofatumumab)
• Aubagio (teriflunomide)
• Tysabri (natalizumab)
• Lemtrada (alemtuzumab)

Medications that are TNF inhibitors that would qualify include:

• Enbrel (etanercept)
• Remicade (infliximab)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Simponi (golimumab)

Medications commonly used for transplant rejection:

• Prograf (tacrolimus)
• Neoral (cyclosporine)
• Imuran (azathioprine)
• Rapamune (sirolimus, rapamycin)
• Cellcept (mycophenolate mofetil)

If you are unsure whether you qualify or not, please do not hesitate to fill out the above form and we will have one of our providers contact you to discuss.

Learn more by watching our videos below:

Contact Atracare Health to schedule an appointment to discuss Covid 19 preventative options with your primary care doctor. Follow us on Facebook  and/or Instagram to get updates as they become available to our community in Southern Delaware.

Learn more about the Covid 19 Treatment options available through Atracare Health >